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Abstract: This work is an attempt to give an overview of the clinical data available on lipid 
based formulations. Lipid and surfactant based formulations are recognized as a feasible approach 
to improve bioavailability of poorly soluble compounds. However not many clinical studies 
have been published so far. Several drug products intended for oral administration have been 
marketed utilizing lipid and surfactant based formulations. Sandimmune® and Sandimmune 
Neoral® (cyclosporin A, Novartis), Norvir® (ritonavir), and Fortovase® (saquinavir) have been 
formulated in self-emulsifying drug delivery systems (SEDDS). This review summarizes 
published pharmacokinetic studies of orally administered lipid based formulations of poorly 
aqueous soluble drugs in human subjects. Special attention has been paid to the physicochemi-
cal characteristics of the formulations, when available and the impact of these properties on the 
in vivo performance of the formulation. Equally important is the effect of concurrent food intake 
on the bioavailability of poorly soluble compounds. The effect of food on the bioavailability of 
compounds formulated in lipid and surfactant based formulations is also reviewed.
Keywords: lipid formulations, poorly soluble compounds, pharmacokinetics, human clinical 
studies, lipophilic compounds, SEDDS, emulsions, food effect
Introduction
The purpose of this article is to review the clinical trials on lipid and surfactant based 
formulations of poorly soluble compounds for oral administration. Despite a plethora 
of articles dealing with orally administered lipid based formulations of poorly soluble 
compounds, the majority of these articles emphasize issues related to pharmacology 
and toxicity rather than formulation issues. Therefore special attention has been paid 
to the differences in the pharmacokinetics upon oral administration of different lipid 
formulations. 
The use of lipid and surfactant based formulations is one of several approaches 
that has been applied in order to improve the oral bioavailability of poorly aqueous 
soluble compounds intended for oral administration. The approach has proved ef-
ﬁ  cient and hence has received attention, especially in academia. Lipid and surfactant 
based systems are physically very different systems including systems like emulsions, 
microemulsion, self-emulsifying drug delivery systems (SEDDS), micellar solutions, 
and dry emulsions like lipid solutions and lipid suspensions. 
The number of excipients which are pharmaceutically acceptable and applicable in 
the formulation of lipid and surfactant based systems is large. The use of solubilizing 
excipients in marketed formulations of poorly soluble compounds has been reviewed 
recently (Strickley 2004).
The bioavailability enhancing properties of lipid and surfactant based systems 
has most often been attributed to the ability of the vehicles to keep the compound in 
solution in the gastrointestinal (GI) tract and thereby maintaining a maximal free drug 
concentration (Porter and Charman 2001). However the underlying mechanisms of Therapeutics and Clinical Risk Management 2007:3(4) 592
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absorption from lipid and surfactant based systems is not 
fully understood.
The majority of the knowledge of the in vivo perfor-
mance and suggested mechanism of drug absorption from 
lipid based formulations originates from studies in animals. 
Several authors have attempted to identify and describe the 
important parameters in order to set-up rational strategies 
for development of new lipid based formulations. The 
parameters that have been emphasized so far are the degree 
of emulsiﬁ  cation (in terms of particle size), and the solubility 
of the drug both in the digested and nondigested formulation 
of the resultant dispersion (Humberstone and Charman 1997; 
Pouton 2000; Porter and Charman 2001; Porter et al 2004; 
Nielsen et al 2007).
Furthermore a number of typically employed excipients 
are susceptible to enzymatic degradation in the GI tract. 
Excipients susceptible to degradation include natural di- and 
triglycerides as well as some commonly used surfactants like 
Labrasol, Labraﬁ  l, Gelucire, Cremophor, Tween 80 (Khossravi 
et al 2002, Seebaluck et al 2004, Larsen et al 2006). 
The release of compound from SEDDS based formulation 
is thought to take place by two major pathways: Interfacial 
transfer and degradation of vehicle (de Smidt et al 2004; 
Porter et al 2004). Interfacial transfer can be described as a 
concentration gradient driven process in which the compound 
diffuses from the formulation into the bulk or directly over 
the intestinal membrane. The rate and extent of interfacial 
transfer is thought to be governed by partition coefﬁ  cient and 
solubility in the donor (formulation) and recipient phase par-
ticle size and hence surface area of formulation (Armstrong 
and James 1980). The second pathway is degradation of 
the vehicle inducing the release of the compound out of the 
vehicle. As mentioned above, for lipid based formulations, 
the most important degradation is the lipolysis catalyzed by 
pancreatic lipase. The release rate is thought to be dependent 
on the solubility of the compound in the formulation and 
rate and extent of the degradation of the vehicle. Lipolysis 
of triacylglycerols (TG) by the pancreatic lipase–colipase 
complex releases monoacylglycerols, diacylglycerols and 
free fatty acids. These lipolysis products are amphiphiles 
that will further assist the solubilization of poorly soluble 
compounds in the GI ﬂ  uids. 
Recently it has been demonstrated that a number of 
excipients should be considered as more than just inert sub-
stances. It has been shown that Cremophor EL, Tween 80, 
Labrasol, Miglyol polyethoxylated, can inhibit the PGP efﬂ  ux 
transporter (p-glycoprotein) (Hugger et al 2002; Shono et al 
2004; Cornaire et al 2004) and hereby potentially improve 
bioavailability of drug molecules being PGP substrates. 
A number of excipients have shown to inﬂ  uence the lym-
phatic transport both in rats, and have an impact to the chy-
lomicron secretion in caco-2 cells, which is also believed 
to be an indicator of lymphatic transport (Rege et al 2002; 
Seeballuck et al 2003; Karpf et al 2004). 
These advances in the characterization of the mecha-
nisms underlying the bioavailability enhancing properties 
of lipid and surfactant based formulations mark a change in 
formulation strategy away from the more empirically based 
formulation testing to a more rational formulation strategy. 
However it also implies that more work is needed in the 
ﬁ  eld and that a battery of different methods should be used 
to describe the different mechanisms. 
Among the lipid based formulations used for oral delivery, 
SEDDS and self-microemulsifying drug delivery systems 
(SMEDDS) have been characterized more systematically 
from a physicochemical point of view. They are isotropic 
mixtures of oil (pure triglyceride oils, mixed glycerides), 
surfactant (hydrophilic or/and lipophilic), water soluble 
co-solvents and the poorly soluble compound. Development 
and characterization of SEDDS and SMEDDS has been 
extensively reviewed (Pouton 1997; Gershanik and Benita 
2000; Gursoy and Benita 2004; Pouton 2006). A number of 
biophysical techniques have been used to characterize these 
systems (Lawrence and Rees 2000). Scattering techniques 
such as dynamic light scattering (DLS) (Constantinides 
and Scarlet 1997), small angle neutron scattering (SANS) 
(Bergenholtz et al 1995) and small angle x-ray scattering 
(SAXS) (Regev et al 1996) can offer useful information 
for the structure of the microemulsions together with freeze 
fracture electron microscopy (Vinson et al 1991). Dielectric 
viscosity, and conductivity measurements can offer new 
insights on the characterization of these systems on a mac-
roscopic level (Acosta et al 1996).
Equally important are the interactions between drugs and 
food. The impact of food on the bioavailability of drugs in 
clinical studies has recently been reviewed by Schmidt and 
Dalhoff (2002). Food delays the gastric emptying rate and 
induces secretion of bile and pancreatic juices, while the pas-
sage time of the small intestine remains virtually unchanged. 
Hence food intake can increase the solubilization time and 
increase the solubility of a poorly soluble drug, which will 
affect the pharmacokinetic parameters.
In the following, data from clinical studies of oral lipid 
based formulations of poorly soluble compounds performed 
are presented. Table 1 summarizes the type of study and the 
formulations used. Therapeutics and Clinical Risk Management 2007:3(4) 593
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For practical reasons the studies presented in the current 
work have been categorized based on the physicochemical 
characteristics (oil, suspensions, emulsions, SEDDS, and 
surfactant based systems). Furthermore the studies on the effect 
of food to oral bioavailability in humans have been reviewed. 
Oil solutions
Lipid based formulations can enhance the bioavailability of 
poorly soluble drug substances by keeping the compound in 
solution. Medium chain triaglycerides (MCT) and long chain 
triaglycerides (LCT) are commonly used for the lipid based 
formulations. Several major differences exist between MCT 
and LCT in respect with their in vivo fate, such as lipolytic 
products, differences in the modulation on gastric emptying 
(Hunt and Knox 1968) and the contraction of the gallbladder 
in humans (Ladas et al 1984). Long chain lipolytic products 
delay gastric emptying and facilitate the contraction of the 
gallbladder to a larger extent than the medium chain lipolytic 
products (Hunt and Knox 1968). 
The bioavailability of quingestrone (progesterone 
3-cyclopentyl enol ether belonging to the enol ethers of 
∆3-kerosteroids) after oral administration to human subjects 
was evaluated by measuring the urinary excretion of 
pregnanediol and allopregnanediols (Bruni and Galleti 1970). 
100 mg of the compound prepared either as micronized 
powder (with particle size less than 10 µm), an oil suspension 
in 0.3 ml of sesame oil (with particle size less than 10 µm), 
or an oil solution in 2.5 ml of sesame oil. Bioavailability of 
quingestrone was determined as the total urinary secretion for 
both metabolites. The urinary excretion was highest when the 
oil solution (6.43 ± 0.18 mg was administered compared with 
the oil suspension (2.96 ± 0.27 mg) or and the micronized 
powder (0.91 ± 0.02 mg). 
The relative bioavailability of clomethiazole (base form) 
was investigated after oral administration of two arachis 
oil formulation both in capsules and a tablet formulation 
to fasting healthy volunteers (Fischler et al 1973). Higher 
plasma concentrations were obtained from the oil ﬁ  lled 
capsules and the absorption was more rapid, compared 
with tablets. The two arachis oil formulations consisted 
of clomethiazole and arachis oil 1:1 (384 mg + 384 mg) 
or 1:2 (384 mg + 768 mg) on a weight basis, respectively. 
Increasing the arachis oil to clomethiazole ratio from 1:1 
to 2:1 resulted in a 1.5 times increase in Cmax suggesting an 
increase in bioavailability with increase of co-administered 
oil amount. Doubling the clomethiazole dose, but keeping 
the oil: drug ratio at 1:1 resulted in a 1.7 times increase Therapeutics and Clinical Risk Management 2007:3(4) 597
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compared with a tablet formulation indicating nonlinear 
absorption kinetics. The results emphasizing the impact of 
the solubilization capacity of the lipid vehicle to the overall 
performance of the formulation
A soft capsule contained 200 mg of ﬂ  ufenamic acid 
(analgesic anti-inﬂ  ammatory agent), 100 mg of vegetable oil, 
40 mg of hydrogenated vegetable oil, 8 mg of beeswax and 
5 mg of soya lecithin and a hard gelatin capsules contained 
200 mg ﬂ  ufenamic acid and 20 mg of magnesium stearate 
were orally administered to healthy volunteers (Angelluci 
et al 1976). The plasma levels more than doubled 90 minutes 
after administration of the lipid solution compared with the 
powder formulation. However after 180 and 360 minutes 
the plasma levels were lower after administration of the soft 
capsules. Due to the low number of plasma samples, it as not 
possible to identify any signiﬁ  cant differences. The different 
plasma curves observed for the two pharmaceuticals forms 
can be attributed to physicochemical factors, triggered by 
excipients present in the soft gelatin capsule which result in 
a faster absorption of the drug.
The absorption of diazepam (benzodiazepine deriva-
tive) in fasted human subjects when dosing 5 mg in either a 
medium chain triglyceride formulation (2% diazepam-MCT 
solution) or a commercially available tablet formulation 
(Serenzin®, Sumitomo Chemical Co) in a crossover study was 
investigated by Yamahira and colleagues (1979). There was 
no signiﬁ  cant difference in the average plasma proﬁ  les arising 
from the two formulations. The authors mainly attributed this 
to the large intersubject variation and the limited number of 
subjects (n = 4) enrolled in the study. However upon repeated 
administrations, the MCT solution showed less intrasubject 
variation. The authors suggested that MCT solution of 
diazepam produced a more uniform drug absorption rate 
compared with the tablets for individual patients.
The impact of the physical characteristics of a formula-
tion has been demonstrated by Hargrove and colleagues 
(1989) in a clinical study with progesterone. Progesterone 
is indicated for use in the prevention of endometrial hyper-
plasia in nonhysterectomized postmenopausal women. Four 
different preparations were made: plain milled progesterone, 
micronized progesterone, plain-milled progesterone in oil, 
micronized progesterone in oil. Suspending the micronized 
progesterone in oil more than doubled the Cmax, compared 
with micronized powder, while there was no effect of 
suspending the nonmicronized progesterone in oil. These 
results emphasize the effect of concomitant lipid digestion 
in dissolution of drug, at the same time also showing that the 
particle size of the solid drug is important.
The effect of medium chain triglyceride was studied by 
Rolan et al in 1994. In this approach, absorption of 500 mg 
atovaqoune (an antiprotozoal agent) from either a suspen-
sion in 30 ml of Miglyol (fractionated coconut oil, medium 
chain triglyceride), an aqueous suspension using 0.25% 
w/v methylcellulose as suspending agent, or two 250 mg 
tablets of atovaquone were used. The AUC values were at 
the same levels for the aqueous and oil suspensions (144 ± 
48 µg/ml–1 hr and 144 ± 124 µg/ml–1 hr respectively), the 
Cmax increased for both formulations (2.7 ± 1.1 µg/ml for the 
aqueous suspension and 2.0 ± 1.8 µg/ml for the oil) compared 
with the tablets (1.1 ± 0.6 µg/ml). The higher absorption of 
atovaquone from the aqueous and oil suspensions compared 
with tablets was attributed to a better dispersion, allowing a 
faster solubilization of the drug. 
Two oil solutions containing long chain and medium 
chain triglycerides with vitamin D were administered in 
human volunteers (Holmberg et al 1990). Higher AUC values 
obtained for the LCT solution (peanut oil) compared with the 
MCT solution (Miglyol 812) suggesting that the presence of 
long chain fatty acids enhance the absorption of vitamin D.
In four out of seven studies the presence of long chain 
triglycerides (LCT) signiﬁ  cantly increased the oral absorption 
of the drugs (Bruni and Galleti 1970; Fischler et al 1973; 
Hargrove et al 1989; Holmberg et al 1990). Furthermore 
LCT formulations demonstrated higher oral absorption 
compared with MCT ones (Holmberg et al 1990). In contrast 
no signiﬁ  cant difference in the absorption observed among 
oil formulations containing medium chain triglycerides MCT 
and tablets (Yamahira et al 1979; Rolan et al in 1994). Finally 
in one case the presence of LCT solutions didn’t enhance the 
absorption of the drug compared with the tablets (Angelluci 
et al 1976). Despite the fact that the results seem to be case 
speciﬁ  c, there are indications that LCT oil solutions perform 
better compared with MCT solutions. However it is rather 
difﬁ  cult to draw conclusions because of the limited number 
of studies and the fact that there are no clear indications of 
which characteristics of a compound that are determining 
whether LCT or MCT oils give better bioavailability.
Emulsions
Another approach to increase the bioavailability of poorly 
water solule drugs is to formulate them in lipid emulsions. 
Bioavailability studies in humans were carried out 
using o/w-emulsions, aqueous suspensions and commercial 
tablets (Bates and Sequeira 1975) of griseofulvin which 
is an antifungal antibiotic and it is commonly used in the 
treatment of dermatophyte infections in humans. Four dosage Therapeutics and Clinical Risk Management 2007:3(4) 598
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forms containing micronized griseofulvin were evaluated 
by administration to humans. The corn o/w emulsion and 
aqueous suspension both contained 300 mg of polysorbate 60 
in emulsion and 500 mg of suspended griseofulvin per 30 g of 
formulation. Two different commercial tablets contained 500 
mg of micronized griseofulvin. The four dosage forms were 
administered in a random cross-over fashion to ﬁ  ve fasting 
subjects in the form of 30 g of the corn oil emulsion, 30 g 
aqueous suspension and the tablets and the drug absorption 
was monitored from urinary excretion data for the major 
metabolite (6-desmethylgriseofulvin). Administration of o/w 
emulsion resulted in a 3–4 fold increase approximately, in the 
maximum excretion rate (mg/hr) of total 6-desmethylgriseo-
fulvin. The bioavailability from the o/w emulsion increased 
2 times compared with the other dosage forms. Such behavior 
attributed to the presence of linoleic acid contained in the 
lipolysis products which may inhibit the GI motility and 
stimulate the gallbladder evacuation.
In a follow up study the effect of different amounts of 
lipid emulsion was investigated (Bates et al 1977). However 
the total 6-desmethylgriseofulvin excretion rate proﬁ  les 
were quite similar after administration of the ultramicrosize 
griseofulvin tablets and 5, 10, 15, and 30 g of o/w emulsion 
used in the that study. 
Lipid and surfactant based systems have been used 
for coenzyme Q10 (ubiquinone) which is a lipid soluble 
antioxidant, suggested to have a positive influence in 
congestive cardiac failure. The absorption of coenzyme Q10 
was followed upon administration in different lipid dosage 
forms (Weis et al 1994). The tested formulations included 
100 mg coenzyme Q10 i) suspended in soy bean oil (400 mg) 
administered in a soft gelatine capsule ii) in a mixture of 
polysorbate 80 (20 mg), phoshatidylcholine (100 mg) and 
soybean oil (280 mg) and iii) in a mixture of polysorbate 
80 (20 mg) and soy bean oil (380 mg). The suspension in 
pure soy bean oil increased the bioavailability of coenzyme 
Q10 signiﬁ  cantly compared with the lipid mixtures that 
included surfactant systems. It was suggested, that possibly 
the formation of mixed micelles containing polysorbate 80 
phosphatidylcholine and soyabean oil for formulation ii) and 
micelles from polysorbate 80 and soyabean oil for formula-
tion iii), in the intestine might induce a decrease of the drug 
solubilization with the bile salts.
Recently the effect of an organized lipid matrix emul-
sion containing lyso-phosphatidylcholine, monoglycer-
ides, and fatty acids (ratio 1:4:2) was given along with 
a traditional capsule formulation of retinyl palmitate 
(Lepage et al 2002). The lipid matrix emulsion yields 
a single melting point (64 °C) which is much lower 
than the melting point of its individual components. It 
produces an eutectic matrix due to the interaction of 
monoglycerides with the lyso-phopshatidylcholine. The 
absorption in cystic fibrosis adolescent patients, who have 
an impaired pancreatic function, was compared with that 
upon administration of the same dose of retinyl palmitate 
given along with a conventional isocaloric TG based 
nutrional supplement. It was concluded that the AUC 
(over baseline) for the organized lipid matrix was 10-fold 
higher compared with the TG based formula. The orga-
nized lipid matrix formula needed no hydrolysis before 
absorption, and could lead to a less variable absorption. 
This organized lipid matrix emulsion has also been tested 
in human subjects with the compound 4-Hydroxylphenyl-
retinamide (4-HPR) a retinoid compound with antileu-
kemic and proapoptotic activity in acute lymphoblastic 
leukemia. The bioavailability of a 4-HPR oral capsule 
formulation resulted in poor patient compliance at higher 
doses (due to the large number of capsules) in phase I 
trials of high-dose oral 4-HPR and high inter-patient 
variations. Using a lipid matrix emulsion it was possible 
to reduce the dose to 20% of the traditional formulation 
and still obtain equivalent peak plasma concentrations 
(Avanti® Polar Lipids, Inc. 2006).
Dry emulsions consisting of redispersed freeze-
dried drug-milk formulations have been evaluated using 
reconstitution in vitro to obtain an o/w emulsion before 
administration for dicumarol (an anticoagulant) (Macheras 
and Reppas 1986a) and nitrofurantoin (a bacteriocidal) 
(Macheras and Reppas 1986b) respectively. Capsules 
containing the pure drugs were used as controls in both 
cases. Analysis of urine data revealed superiority of 
the nitrofurantoin-milk formulations regenerated with 
200 and 400 ml of milk over the corresponding capsule 
formulations in the rates and extents of nitrofurantoin 
excretion. Determination of the plasma dicumarol levels 
indicated superiority of the dicumarol-milk formulation. 
Statistically significant differences were found between 
area under the curve, maximum plasma concentration, 
and apparent elimination rates. 
The introduction of the organized lipid matrix emulsion 
which can be used with further hydrolysis is an interesting 
approach. The main advantage of this formulation is that no 
hydrolysis is needed which can result in less variations in 
absorption. However it is rather difﬁ  cult to draw conclusions 
for the applicability of this formulation since the data from 
the literature are quite limited at the moment. Furthermore Therapeutics and Clinical Risk Management 2007:3(4) 599
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the potential of the drug-milk freeze-dried formulations for 
the enhancement of the bioavailability of sparingly water 
soluble drugs are not yet elucidated.
Self emulsifying drug delivery 
systems
Self (micro) emulsifying drug delivery systems have attracted 
a lot of attention lately. Their thermotropic stability and the 
high drug loading efﬁ  ciency make them a promising system 
for poorly water soluble drugs giving particles with small 
size.
Julianto and colleagues (2000) demonstrated that a 
SEDDS increased the bioavailability of α-tocopherol 
approximately 210%–410% compared with a commercially 
available soybean oil solution. The antioxidant α-tocopherol, 
a lipid soluble vitamin (vitamin E), is a poorly aqueous 
soluble compound. Traditionally α-tocopherol has been 
formulated as a capsule containing a simple oil solution. 
Both the SEDDS and the commercial α-tocopherol formula-
tion contained 400 mg α-tocopherol. The SEDDS contained 
Tween 80: Span 80: Vitamin E (4:2:4) and the commercial 
formulation contained of α-tocopherol dissolved in soy bean 
oil. Both the AUC0–∞ and Cmax values of the SEDDS were 
markedly higher than those of the oil solution, while the Tmax 
was shorter, indicating a higher rate and extent of absorption. 
No physicochemical characterization was performed and it 
was not stated if the lipid amount were equal between the 
formulations. 
In a recent study the bioavailabilities of three different 
lipid formulations of tocotrienols (Yap et al 2004) were 
investigated. Two self-emulsifying systems SEDDS, 
containing varying amounts of soybean oil, Tween 80 and 
Labrasol (C8/C10 polyglycolyzed glycerides from coconut 
oil) was analysed according to their self-emulsifying 
properties, droplet sizes and extent of lipolysis. The droplet 
size was 1.5 and 10.6 µm respectively. Formulations con-
taining 200 mg mixed tocotrienols administered in healthy 
adults as SEDDS or simple soybean oil solution stated that 
the SEDDS had markedly higher plasma levels and a faster 
onset of absorption compared with the oily solution. The 
droplet size difference between the two SEDDS did not affect 
the bioavailabilities. However, the total dosed lipid amounts 
between the three explored formulations ranged from 
31.3–351.3 mg soybean oil thus making the interpretation 
of the bioavailabilities more complex. 
The potent anti-HIV drug saquinavir has been enrolled 
in studies with human subjects in lipid based formulations. 
It has been formulated into SEDDS. The drug is available in 
the market in both hard gelatine capsule (Invirase), containing 
saquinavir with lactose microcrystalline cellulose, povidone 
K30, sodium starch glycolate, talc and magnesium stearate 
and soft gelatin capsules (Fortovase), containing saquinavir 
in solutions in medium chain mono- and -diglycerides, 
povidone and dl-alpha tocopherol. In a recent study (Roche 
Laboratories, Inc 2004), a signiﬁ  cant improvement to the 
bioavailability up to 331% of soft gelatine capsules compared 
with hard gelatine capsules. Ritonavir (Norvir) is available 
as in soft gelatin capsules with oleic acid, ethanol, polyoxyl 
35 castor oil titanium dioxide, iron oxide and butylated 
hydroxytoluene (FDA 2006). 
When healthy subjects were administered with saquinavir/
ritonavir 1600 mg/100 mg, and no difference in AUC0–24 
values between hard and soft gelatine capsules was observed, 
respectively (Cardiello et al 2003). The pharmacokinetics 
and the safety of a boosted saquinavir/ritonavir combination 
either with hard gelatin capsules or soft gelatin capsules was 
evaluated (Kurowski et al 2003). Comparable plasma expo-
sures with saquinavir achieved when saquinavir boosted with 
ritonavir, accompanied by an improvement in gastrointestinal 
system disorders.
The turning point for development of the oral lipid and 
surfactant based formulations of poorly soluble drugs was 
the introduction to the market of cyclosporine A (CsA) in a 
lipid based formulation. CsA is an immuno suppressant used 
in chronic treatment of organ transplant receivers to sup-
press graft rejection and in the treatment of severe rheumatic 
arthritis and severe psoriasis.
The Sandimmune and Sandimmune Neoral formulations 
of CsA are perhaps the best known examples of a marketed 
lipid and surfactant based systems and the pharmaco  kinetic 
has been studied and reviewed extensively (Holt et al 1994; 
Ritschel 1996). Cyclosporine was introduced in 1981 in 
Europe in a self-emulsifying formulation (Sandimmune) 
containing Labraﬁ  l M 1944 CS (polyoxyethylated oleic 
glycerides), olive oil and ethanol (Klyashchitsky and Owen 
1998). This formulation disperses, when diluted with water, 
into a polydisperse oil-in-water macroemulsion. In 1994 a new 
self-microemulsifying formulation (Sandimmune Neoral, 
referred to as Neoral in the following) was introduced, 
which emulsiﬁ  es spontaneously into a microemulsion with a 
particle size smaller than 100 nm. This formulation contains 
Cremophor RH40 (polyoxyl hydrogenated castor oil), corn 
oil glycerides, propylene glycol and ethanol (Klyashchitsky 
and Owen 1998).
Drewe and colleagues investigated the absorption of 
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Sandimmune as reference in fasting healthy volunteers. 
Two of the experimental formulations were microemul-
sions with respectively fast and slow in vitro release. The 
microemulsions were formulated using polyethylene glycol, 
hydrogenated castor oil, medium chain triglycerides and low 
molecular weight glycols. The last experimental formula-
tion was a solid micellar solution with fast in vitro release 
composed of sucrose monolaurate and propylene glycol. 
The fast releasing microemulsion and the fast releasing 
solid micellar solution exhibited signiﬁ  cant higher Cmax and 
bioavailability (141% and 139% of Sandimmune, respec-
tively). The slow releasing microemulsion was equivalent 
to Sandimmune with respect to Cmax and bioavailability. 
The Tmax of the tested formulations were in the same range 
(Drewe et al 1992).
Mueller and colleagues (1994a) investigated the dose 
linearity of CsA from Sandimmune and Neoral in healthy 
volunteers who had been fasting 12 h prior to and 4 h after 
administration ﬁ  nding that Neoral exhibited linear dose 
AUC relationship in the range of 200 to 800 mg in contrast 
to Sandimmune. The relative bioavailability of Neoral 
compared with Sandimmune was found to be in the range of 
174–239% but dependent on the actual dose, with the high-
est dose resulting in the largest difference en bioavailability. 
It must be noted that the bioavailability for Neoral and a 
number of the generic products of CsA exhibited marked 
pharmacokinetic variations in different human subpopula-
tions even though they had been found bioequivalent. This 
discussion is however beyond the scope of this article and has 
been reviewed recently elsewhere (Dunn et al 2001; Pollard 
et al 2001). Studies in fasted healthy volunteers comparing 
Sandimmune (300 mg CsA) and Neoral (180 mg CsA) it was 
found that Neoral exhibit shorter Tmax and higher Cmax and 
AUC (Mueller et al 1994a, 1994b; Kovarik et al 1994).
Recently an experimental CsA self-emulsifying 
galactolipid formulation has been compared with Neoral 
in fasting healthy volunteers (Odeberg et al 2003). 
The self-emulsifying galactolipid formulation forms an 
emulsion with mean particle size of 16–20 µm. The galac-
tolipid formulations exhibited identical Tlag and Tmax but 
slightly lower Cmax (94%) and AUC (84%) when compared 
with Neoral (Odeberg et al 2003). In another study the 
bioavailability of a non-SMEDDS, which is semisolid opaque 
oily suspension that in aqueous solution forms particles 
with a mean diameter 200 nm, and a SMEDDS formula-
tion of cyclosporine were tested (Postolache et al 2002). 
The results showed that the non-SMEDDS formulation was 
not bioequivalent with the SMEDDS formulation due to 
a statistical signiﬁ  cant lower absorption rate. The authors 
claimed that with this study it has been demonstrated that in 
vivo the non-SMEDDS capsules are not totally interchange-
able compared with the SMEDDS capsules. In a different 
approach cyclosporine lipid nanoparticles (lipospheres) 
were developed (Bekerman et al 2004) and the effect of 
composition and particle size investigated. These lipospheres 
consisted of phospholipids, Span 80, Tween 80, Tricaprin, 
and Cremophor RH 40. Cyclosporin dispersions systems 
resulting in particle size of 25 up to 400 nm prepared. Oral 
bioavailability indicated a correlation between the AUC 
and Cmax and the particle size of the dispersion showing the 
highest values for particles with 25 nm diameter. The clini-
cal formulation of Neoral used as a reference. This study 
demonstrated a correlation between the particle size and the 
oral bioavailability of cyclosporine formulations. Further-
more the composition and possibly the surface properties 
of the lipid nanoparticles (lipospheres) could affect the oral 
bioavailability of cyclosporine. 
The above clearly demonstrate that SEDDS can be a 
promising formulation approach for poorly water soluble 
drugs. The efﬁ  ciency of these systems is rather case-speciﬁ  c 
depending on the composition of the formulation used each 
time. 
Surfactant-based solutions
Cremophor is commonly used excipient in lipid-based 
formulations (Strickley 2004). Cremophor EL may inhibit 
PGP (p-glycoprotein), a relevant efﬂ  ux pump which is 
expressed in high amount in gut, biliary tract and the blood 
brain barrier, and enzymes like CYP3A which may contribute 
to ﬁ  rst pass metabolism.
Cremophor EL, is used as a vehicle for the solubilization 
of a wide variety of hydrophobic drugs, including anesthetics, 
photosensitizers, sedatives, immunosuppressive agents and 
anticancer drugs including the anticancer agent paclitaxel 
(Taxol). 
The role of the surfactants Cremophor EL and Tween 80 
and the absorption rate of paclitaxel was investigated 
by Malingre and colleagues (2001). In this study the 
2 formulations were tested; 6 mg/ml paclitaxel in Cremo-
phor EL: ethanol 1:1 v/v or in polysorbate 80: ethanol 1:1 
v/v. The Polysorbate 80 formulation performed better than 
Cremophor EL formulation, both with regard to AUC and 
Cmax. The results demonstrated that the presence of Cremo-
phor EL limited the oral absorption of paclitaxel and they 
highlight the need of designing a better drug formulation in 
order to increase the oral absorption of paclitaxel.Therapeutics and Clinical Risk Management 2007:3(4) 601
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In another approach (Martin-Facklam et al 2002) 
saquinavir in hard gelatine capsules (Invirase) was 
administered with increasing doses of Cremophor EL 
(up to 5 g) in volunteers by mixing the content of Invirase 
capsules with the appropriate amount of Cremophor EL 
and dispersing it into hard gelatine capsules. When 5 g 
Cremophor EL were administered the Cmax of saquinavir 
increased from 8.8 ± 8.5 nmol/l for control (Invirase capsule) 
to 112.7 ± 74.7 nmol/l respectively. Increasing levels of 
Cremophor increased the AUC of saquinavir. It is suggested 
that Cremophor EL acts as a modulator of the absorption 
process by inhibiting intestinal PGP.
Barker and colleagues (2003) explored a 50% (w/w) solid 
dispersion of α-tocopherol in Gelucire 44/14 that comprises 
a mixture of pegylated fatty acid esters and glycerides. Com-
pared with a commercial oil solution of α-tocopherol a two-
fold increase in absorption was found after administration of 
the solid dispersion of α-tocopherol. The AUC0–∞ and Cmax 
were considerably higher after administration of the solid dis-
persion compared with the commercial product. Additionally, 
the lag phase prior to absorption of α-tocopherol from the 
solid dispersion was markedly shorter than for the com-
mercial oil solution. Interestingly, the absorption proﬁ  le 
appeared to be bi-phasic with a second peak after 10 hours, 
presumably due to a 10 h post-dose meal. The fact that this 
second phase of the absorption of α-tocopherol occurred 
after the volunteers were fed (at 10 h post-dose) according 
to the authors was possible due to the mobilisation of the 
lipid-absorbing pathway in response to food.
The data with surfactant-based formulations are too 
limited to draw safe conclusions on and more studies 
are needed to clarify their role since many possible 
mechanisms are in play. New excipients like Gelucire 
and Labrasol can solubilize many drugs and will pos-
sibly be used more frequently in the future. They are 
similar to the Labrafil and they consist of mixtures of 
mono-, di- and triglycerides and mono- and di-fatty acid 
esters of polyethyleneglycol with fatty acid compositions. 
However how these excipients perform in vivo is a crucial 
parameter for their success.
Food effect
The food-drug interactions may depend on several factors 
such as the physical and chemical characteristics of the drug, 
the size and the composition of the meal or the time of drug 
intake in relation with the meal (Singh 1999). 
A claimed advantage of certain lipid-based formula-
tions is that the food effect on poorly soluble drug can be 
diminished as it has been demonstrated by Mueller and 
colleagues (1994b). 
The impact of a high-fat meal on the pharmacokinetics 
of CsA from Sandimmune and Neoral has been investigated 
in healthy volunteers. In a study comparing Sandimmune 
(300 mg CsA) and Neoral (180 mg CsA) it was found 
that food inﬂ  uences the pharmacokinetics of CsA from 
Sandimmune more profoundly than from Neoral. A signiﬁ  -
cant prolongation of Tlag and Tmax and an increase in AUC 
was found for Sandimmune (Mueller et al 1994b). For the 
Neoral formulation the Tlag and Tmax were only slightly and 
insigniﬁ  cantly increased whereas both Cmax and AUC were 
reduced though signiﬁ  cantly (Mueller et al 1994b). In the 
fasted state the relative bioavailability of CsA from Neoral 
was slightly higher (114% of Sandimmune) compared with 
Sandimmune but when administered after a high-fat meal 
the bioavailability from Neoral was considerable lower 
(71.4% of Sandimmune) than from Sandimmune (Mueller 
et al 1994b). In another study in which healthy volunteers 
was administered 7.5 mg/kg CsA after a high-fat breakfast 
it was found that the bioavailability of Neoral was 109.3% 
compared with Sandimmune (Gonzalez-Llaven et al 1999). 
The difference in relative bioavailability of Neoral compared 
with Sandimmune in the two studies performed by Mueller 
and colleagues (1994b) and Gonzalez-Llaven and colleagues 
(1999), could be explained by the difference in dose. When 
correcting the relative bioavailability for the difference in 
dose under the assumption of linear pharmacokinetics in 
the study by Mueller et al the bioavailability of Neoral is 
190% and 119% of Sandimmune in fasted and fed state 
respectively. This emphasizes the importance of adminis-
tering equal doses when investigating the food effect on 
different formulations.
The concentration versus time proﬁ  le for Sandimmune 
show, for a considerable number of individuals, two peaks in 
both fasting individuals (Mueller et al 1994a, 1994b; Kovarik 
et al 1994) and individuals fed a high-fat breakfast (Mueller 
et al 1994b). This could suggest that the absorption of CsA 
from the Sandimmune formulation was limited by gastric 
emptying or the food consumed 4 h after administration.
A lipid emulsion of danazol was dosed to human subjects 
and the pharmacokinetics was studied (Charman et al 1993). 
A commercial formulation as a powder (hard gelatin capsule) 
and a lipid emulsion formulation of danazol were tested 
in both fed and fasted states. The commercial formulation 
contained 100 mg danazol in a capsule and the lipid formu-
lation contained 3.43 mg of danazol per gram of emulsion 
dose. The lipid phase of the emulsion consisted of glycerol Therapeutics and Clinical Risk Management 2007:3(4) 602
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mono-oleate. In the fasted state the AUC for the lipid based 
formulation was 5 time higher than the powder formulation. 
However, no signiﬁ  cant difference observed between the two 
formulations in the fed state. 
Unfortunately the data from the literature are rather 
limited can not give a clear answer to the question, whether 
the lipid formulations are able to overcome food effect.
Summary
Oral route is the preferred for the administration of drugs. 
Since a lot of potential drug candidates are poorly soluble 
in water, resulting in poor and variable oral bioavailability, 
many approaches have been employed in order to produce 
formulations with a high and reproducible bioavailability. 
Development of lipid based formulations has recently 
attracted a lot of attention. Lipid based systems are deﬁ  ned 
as emulsions, microemulsion, SEDDS, micellar suspensions, 
and oil solutions. However, most proof of concept studies 
have been carried out using animal models. As is obvious 
from the above the number of clinical studies evaluating the 
beneﬁ  ts of lipid based formulations is rather limited. The 
clinical data described in this article indicates that the stud-
ies could be separated in two different time-periods, based 
on the design and the performed clinical trials. In the ﬁ  rst 
period which covers the period from the early sixties up to 
late eighties the lipid formulations mainly consist of an oil 
solution of the drug or an oil macroemulsion. The physi-
cochemical characterization at this stage is rather poor or 
nonexisting. But in almost all the cases the lipid formulations 
or emulsions performed better than the tablets. 
The second period for lipid based formulations starts in 
the ﬁ  rst half of the 1990s, with the entrance in the market 
of a SMEDDS (Neoral) of cyclosporine which produces a 
ﬁ  nely dispersed microemulsion when diluted in an aque-
ous phase emphasized the impact of the physicochemical 
properties of the lipid vehicles compared with formulations 
tested before. 
A number of studies have reported higher bioavailability 
with decreased particle size when comparing self-emulsify-
ing formulations (Drewe et al 1992; Kovarik et al 1994; Gao 
et al 1998; Odeberg et al 2003). However the formulations 
investigated in these studies made use of either different 
surfactant and lipid phases or different ratios between the 
surfactant and the lipid phase. This fact impedes a conclu-
sion with regard to the optimal composition of SMEDDS, 
since it is well described that formulations with matching 
particle size but different lipid phases can exhibit different 
bioavailability values (Khoo et al 1998).
The choice of surfactants and lipids is a crucial factor 
for the in vivo fate of the formulation. The lipids play a 
signiﬁ  cant role since they can increase the drug solubility 
in lumen, can change the physical (Aungst 2000) and the 
biochemical barrier function (Benet 2001) of the GI tract 
and they can stimulate the lymphatic transport (Porter and 
Charman 1997). 
Furthermore the food-drug interactions are important to 
drug absorption. Concomitant food intake has been demon-
strated to lead to an increase in drug bioavailability. However 
when a microemulsion was administered a reduced effect of 
food on bioavailability was noticed (Mueller et al 1994b). 
The fact that only four drug products, Sandimmune® and 
Sandimmune Neoral® (cyclosporin A), Norvir® (ritonavir), 
and Fortovase® (saquinavir) are on the market in combina-
tion with the hydrophobic nature of many drug candidates 
implies that the studies with lipid based formulations have 
to be more intensive and more systematic. 
Finally the stability of these formulations is a parameter 
that has been rather underestimated since there is lack of stud-
ies and data on this issue. However the success of the each 
formulation in perspectives of being released in the market 
as a commercial product is highly dependant on its stability 
in long term, therefore more studies are required.
In conclusion more human bioavailability studies are 
needed to elucidate the mechanisms of action of these formu-
lations. In parallel the development of new formulations well 
characterized in terms of their physicochemical properties 
will offer new insights on their performance in vivo.
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